The acute bronchodilator effects of a single dose (2 puffs) of the short-acting anticholinergic ipratropium bromide (40 mcg) and the short-acting beta-adrnergic fenoterol (200 mcg) in comparison to placebo on top of pharmacodynamic steady state of once-daily tiotropium (18 mcg) inhalation capsule in (patients with chronic obstructive pulmonary disease)

Trial Profile

The acute bronchodilator effects of a single dose (2 puffs) of the short-acting anticholinergic ipratropium bromide (40 mcg) and the short-acting beta-adrnergic fenoterol (200 mcg) in comparison to placebo on top of pharmacodynamic steady state of once-daily tiotropium (18 mcg) inhalation capsule in (patients with chronic obstructive pulmonary disease)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2009

At a glance

  • Drugs Fenoterol; Ipratropium bromide; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top